Patents Issued in November 12, 2024
-
Patent number: 12138280Abstract: Methods and systems are provided for preparing a ready-to-use peritoneal dialysis fluid for peritoneal dialysis of a patient having a deficiency in potassium. The methods comprise mixing, immediately before administration to the patient, appropriate amounts of at least a first concentrate, a second concentrate, and a third concentrate with an appropriate amount of water to form a ready-to-use dialysis fluid. The first concentrate comprises glucose, has a pH of between 1.5 and 4, and is free of potassium ions; the second concentrate comprises a physiologically acceptable buffer and is free of potassium ions; and the third concentrate comprises the physiologically acceptable buffer and potassium ions.Type: GrantFiled: October 25, 2018Date of Patent: November 12, 2024Assignee: GAMBRO LUNDIA ABInventors: Anders Wieslander, Olof Jansson, Anders Wellings
-
Patent number: 12138281Abstract: The invention relates to method of treating chronic inflammatory diseases in subjects in need thereof by administering calcium lactate as an active agent. The calcium lactate can be provided in a pharmaceutical, food, or nutrient composition.Type: GrantFiled: May 9, 2023Date of Patent: November 12, 2024Assignee: METIMEDI PHARMACEUTICALS CO., LTD.Inventors: Chong-Hwan Chang, Keun-Yeong Jeong
-
Patent number: 12138282Abstract: Described herein are companion methods and kits useful for IL-2-based therapies and for mesenchymal stem cell-based therapies.Type: GrantFiled: June 2, 2016Date of Patent: November 12, 2024Assignee: AELAN CELL TECHNOLOGIES, INC.Inventors: Victoria Lunyak, Meenakshi Gaur
-
Patent number: 12138283Abstract: Provided is a method of preparing a three-dimensional cell spheroid, the method including forming the cell spheroid by co-culturing adipose-derived stem cells or mesenchymal stem cells with hepatocytes. According to the cell spheroid prepared by the method, the secretome secreted by the adipose-derived stem cells affects hepatocyte maturation, and therefore, hepatic functions of the finally formed three-dimensional cell spheroid, i.e., organoid, may be enhanced. Further, a composition including a culture medium of the adipose-derived stem cells may prevent or treat liver diseases including hepatitis, hepatotoxicity, cholestasis, fatty liver, etc., and may enhance hepatic functions.Type: GrantFiled: May 15, 2019Date of Patent: November 12, 2024Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Sang-Heon Kim, Seokheon Hong, Seung Ja Oh, Kwi Deok Park
-
Patent number: 12138284Abstract: The present disclosure encompasses methods for generating cells or tissue from existing cells with one or more mutated variants of Yap. In specific embodiments, the disclosure regards treatment of existing cardiomyocytes with one or more mutated variants of Yap that causes them to divide and generate new cardiomyocytes. In specific cases, the mutated variant of Yap has serine-to-alanine substitutions at 1, 2, 3, 4, 5, 6, or more serines of Yap.Type: GrantFiled: September 12, 2022Date of Patent: November 12, 2024Assignee: BAYLOR COLLEGE OF MEDICINEInventors: Tanner Monroe, John Leach, James F. Martin
-
Patent number: 12138285Abstract: Microbes expressing cholesterol oxidoreductase (COR) proteins, methods of engineering the microbes expressing COR proteins, compositions and methods of using the microbes are provided.Type: GrantFiled: March 6, 2023Date of Patent: November 12, 2024Inventors: Douglas Kenny, Hera Vlamakis, Ramnik Xavier, Emily Balskus, Damian Plichta
-
Patent number: 12138286Abstract: The present application describes methods of treating or reducing the onset or occurrence of childhood atopic disease. In particular, it relates to an integrated solution that accounts for temporal and sequential administrations of three different and specific approaches for optimal effectiveness in treating or reducing the onset or occurrence of childhood atopic disease.Type: GrantFiled: November 27, 2023Date of Patent: November 12, 2024Assignee: Johnson & Johnson Consumer Inc.Inventors: Richard A. Insel, Linda Alunkal, Russell Gould
-
Patent number: 12138287Abstract: A usage of a Antrodia cinnamomea powder for preparation of a composition for dispelling the effects of alcohol, which means that by administering an effective amount of the Antrodia cinnamomea powder disclosed in the invention to an subject, is capable of accelerating metabolism of alcohol and/or acetaldehyde in the subject's body, reducing a content of alcohol and/or acetaldehyde in blood, and shortening the time of the subject generating intoxicated reaction in order to achieve an efficacy of dispelling the effects of alcohol.Type: GrantFiled: July 24, 2023Date of Patent: November 12, 2024Assignee: GREENYN BIOTECHNOLOGY CO., LTDInventors: Pang-Kuei Hsu, Chia-Feng Wu
-
Patent number: 12138288Abstract: Synergistic herbal compositions comprising combination of a first ingredient selected from the extract(s), fraction(s), active compound(s) and phytochemicals or mixtures thereof derived from the plant parts of Punica granatum and a second ingredient selected from the extract(s), fraction(s), active compound(s) and phytochemicals or mixtures thereof derived from the plant parts of Theobroma cacao for improving testosterone levels.Type: GrantFiled: May 8, 2019Date of Patent: November 12, 2024Assignee: LAILA NUTRACEUTICALSInventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Kiran Bhupathiraju, Trimurtulu Golakoti, Venkata Kanaka Ranga Raju Gokaraju, Venkateswarlu Somepalli, Venkata Krishna Raju Alluri
-
Patent number: 12138289Abstract: An improved method for making cannabigerol (CBG) utilizing the following steps. CBG-containing material is contacted with an aqueous alkaline solution containing a hydroxide base and essentially no organic solvents, thereby extracting cannabinoids including carboxylic acids and salts and producing an alkaline extract. Non-soluble CBG-containing material is removed from the alkaline extract to produce a clarified alkaline extract. The extracted cannabinoids are decarboxylated and the resulting cannabigerol is crystallized/precipitated from the clarified alkaline extract at a pH greater than 7.Type: GrantFiled: July 13, 2023Date of Patent: November 12, 2024Assignee: M-For, LLCInventor: Zachary White
-
Patent number: 12138290Abstract: The present invention relates to developing a plant-based composition for arresting the spread of pathogens from an infected person which can be sprayed in infected places, for rapidly decontaminating the affected areas thereby arresting the spread in larger areas which includes include, office complexes, hospitals, schools, mass transportation, prisons, care facilities, public housing, and mass transportation terminals. The present composition is a mixture containing herbs including lavender, Chinese skullcap, black seed oil, Sida acuta, cryptolepis, Isatis, licorice, sage, medicinal honey and ginger in a colloidal silver base.Type: GrantFiled: December 30, 2020Date of Patent: November 12, 2024Inventor: David Paul Kutchinski
-
Patent number: 12138291Abstract: [Problem to be Solved] It is intended to provide a composition for hemostasis which can be uniformly applied to a bleeding site and exerts a high hemostatic effect. [Solution] The present invention provides a composition to be applied as a spray to a subject, the spray being used for hemostasis, and the composition comprising a self-assembling peptide, wherein the self-assembling peptide self-assembles and thereby gels when the composition is applied to a bleeding site of the subject, and the self-assembling peptide is contained in the composition at a concentration at which the composition has an improved hemostatic ability as compared with that when directly applied.Type: GrantFiled: March 17, 2022Date of Patent: November 12, 2024Assignee: 3-D Matrix, Ltd.Inventors: Keiji Nagano, Satoru Kobayashi
-
Patent number: 12138292Abstract: The invention relates to novel compounds with the ability to link an immune response to a pathogen, to the use of said compounds in a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.Type: GrantFiled: June 13, 2022Date of Patent: November 12, 2024Assignee: Centauri Therapeutics Limited (GB/GB)Inventors: Michael Westby, Melanie Glossop, Christine Watson
-
Patent number: 12138293Abstract: This disclosure provides formulations suitable for topical ophthalmic delivery of peptide therapeutics. The disclosure also provides compositions and methods for treating ocular injury. The compositions and formulations may include therapeutically active alpha connexin peptides.Type: GrantFiled: October 22, 2021Date of Patent: November 12, 2024Assignee: XEQUEL BIO, INC.Inventors: Gautam Ghatnekar, Christina Grek
-
Patent number: 12138294Abstract: Aspergillus flavus is an opportunistic, saprophytic fungus that infects maize and other fatty acid-rich food and feed crops and produces toxic and carcinogenic secondary metabolites known as aflatoxins. In vitro studies showed a five-fold increase in antifungal activity of AGM182 (vs. tachyplesin1) against A. flavus. Transgenic maize plants expressing AGM182 under maize Ubiquitin-1 promoter were produced through Agrobacterium-mediated transformation. PCR products confirmed integration of the AGM182 gene, while RT-PCR of maize RNA confirmed the presence of AGM182 transcripts. Maize kernel screening assay using a highly aflatoxigenic A. flavus strain (AF70) showed up to 72% reduction in fungal growth in the transgenic AGM182 seeds compared to isogenic negative control seeds.Type: GrantFiled: July 3, 2023Date of Patent: November 12, 2024Assignees: GENVOR INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Jesse M. Jaynes, Kanniah Rajasekaran, Jeffrey W. Cary, Ronald Sayler, Rajtilak Majumdar
-
Patent number: 12138295Abstract: A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequence subcutaneous doses.Type: GrantFiled: March 25, 2021Date of Patent: November 12, 2024Inventors: Omoniyi Adedokun, Daphne Chan, Yang Chen, Philippe Szapary
-
Patent number: 12138296Abstract: This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides methods of using, a lyophilized or powdered form of, and processes for, preparing the formulation.Type: GrantFiled: February 2, 2022Date of Patent: November 12, 2024Assignee: ELANCO US INC.Inventors: Alan Voskamp Klotz, Catherine Ngan Kha, Juan Davagnino
-
Patent number: 12138297Abstract: The present invention relates to collagen hydrolysate for use as an active substance in the treatment of inflammatory skin disorders and intestinal disorders and/or skin disorders and intestinal disorders accompanied by inflammation.Type: GrantFiled: June 17, 2021Date of Patent: November 12, 2024Assignee: GELITA AGInventors: Stephan Hausmanns, Steffen Oesser, Franziska Dolle, Hans-Ulrich Frech
-
Patent number: 12138298Abstract: The present invention relates to a vector for use in the treatment of a polyglutamine repeat spinocerebellar ataxia, which vector comprises cholesterol 24-hydroxylase encoding nucleic acid.Type: GrantFiled: January 30, 2018Date of Patent: November 12, 2024Assignees: BRAINVECTIS, INSERM (INSTITUT NATIONAL DE LA SANTËET DE LA RECHERCHE MÊDICALE), UNIVERSIDADE DE COIMBRA, CENTRO DE NEUROCIÊNCIAS BIOLOGIA CELULARInventors: Sandro Alves, Nathalie Cartier-Lacave, Luis Pereira De Almeida, Clévio Nobrega, Liliana Mendonça
-
Patent number: 12138299Abstract: Disclosed herein are methods for enhancing an immune response in an individual in need thereof. The methods, in certain aspects, may comprise administering bacterial aldehyde dehydrogenase, a bacteria that produces aldehyde dehydrogenase, or combinations thereof to an individual. Further disclosed are compositions, such as nutritional compositions, which may comprise bacterial aldehyde dehydrogenase, a bacteria that produces aldehyde dehydrogenase, or combinations thereof.Type: GrantFiled: April 3, 2024Date of Patent: November 12, 2024Assignee: Children's Hospital Medical CenterInventor: Theresa Alenghat
-
Patent number: 12138300Abstract: A method of promoting compensatory plasticity of spared neural cells after a neural injury includes contacting the spared neural cells with an effective amount of a therapeutic agent comprising a therapeutic peptide, wherein the therapeutic peptide comprises an amino acid sequence with at least 70% identity to SEQ ID NO:32.Type: GrantFiled: August 29, 2019Date of Patent: November 12, 2024Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Jerry Silver, Yu Luo, Fucheng Luo
-
Patent number: 12138301Abstract: The invention features a compound including a mutant KRAS sequence and a lipid, where the mutant KRAS sequence is conjugated to the lipid by a linker, and (i) the linker includes one or more polyethylene glycol blocks, (ii) the lipid is 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and (iii) the mutant KRAS sequence comprises or consists of the amino acid sequence selected from the group consisting of SEQ ID NOs:1-7 and 22-30. The invention features a composition including one or more compounds of the invention and a pharmaceutically acceptable carrier. The invention also features a method of treating a cancer in a human patient, the method including administering the composition to the patient. Further, the invention features a kit comprising the compound.Type: GrantFiled: March 1, 2019Date of Patent: November 12, 2024Assignee: Elicio Therapeutics, Inc.Inventors: Peter C. Demuth, Julian Adams, Martin Steinbuck
-
Patent number: 12138302Abstract: This invention relates to compositions that include a polypeptide derived from E. coli or a fragment thereof; and modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof, and methods of use thereof.Type: GrantFiled: October 25, 2021Date of Patent: November 12, 2024Assignee: Pfizer Inc.Inventors: Annaliesa Sybil Anderson, Laurent Oliver Chorro, Robert George Konrad Donald, Jacqueline Marie Lypowy, Rosalind Pan
-
Patent number: 12138303Abstract: A multivalent immunogenic composition is provided, including one or more recombinant proteins selected from the group consisting of a recombinant attenuated Staphylococcus pseudintermedius Protein A (SEQ ID NO:2), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin S (SEQ ID NO:4), a recombinant attenuated Staphylococcus pseudintermedius Nucleotidase adenosine synthase protein (AdsA) (SEQ ID NO:6), a recombinant attenuated Staphylococcus pseudintermedius coagulase (SEQ ID NO:8), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin F (SEQ ID NO:10), and a recombinant attenuated Staphylococcus pseudintermedius exotoxin 15 (SEQ ID NO:12). Synthetic genes expressing the attenuated recombinant proteins and optimized for expression in E. coli are provided. Vaccines and therapeutic compositions comprising the one or more recombinant proteins are provided.Type: GrantFiled: July 30, 2021Date of Patent: November 12, 2024Assignee: University of Tennessee Research FoundationInventors: Stephen A. Kania, David Bemis, Mohamed A. Abouelkhair
-
Patent number: 12138304Abstract: The technology is directed to HIV envelopes which comprise sequence modifications wherein these modifications prevent CD4-induced transitions of the HIV envelope. Specifically, the disclosure provides recombinant HIV-1 Env proteins comprising mutations, wherein the envelope is a protomer, and wherein three protomers form a trimer stabilized by the presence of the mutations. Provided also are compositions comprising envelopes of the technology, and methods of use.Type: GrantFiled: September 5, 2019Date of Patent: November 12, 2024Assignee: Duke UniversityInventors: Rory Henderson, S. Munir Alam, Barton F. Haynes, Kevin J. Wiehe
-
Patent number: 12138305Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.Type: GrantFiled: March 28, 2022Date of Patent: November 12, 2024Assignee: The Trustees of the University of PennsylvaniaInventors: Drew Weissman, Norbert Pardi
-
Patent number: 12138306Abstract: Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); a modified pre-fusion respiratory syncytia virus (RSV) F protein; and a trimerization domain. Disclosed are nucleic acid sequences capable of encoding peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); a modified pre-fusion respiratory syncytia virus (RSV) F protein; and a trimerization domain. Also disclosed are methods for eliciting a protective immune response against RSV comprising administering to a subject an effective amount of a composition comprising a monomeric Fc fragment of an immunoglobulin recognized by FcRn; a modified pre-fusion RSV F protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.Type: GrantFiled: June 3, 2022Date of Patent: November 12, 2024Assignee: University Of MarylandInventors: Xiaoping Zhu, Weizhong Li
-
Patent number: 12138307Abstract: Crude aqueous extracts of Quillaja saponaria Molina containing at least the QS-21 main peak and 2018 component, wherein the ratio of 2018 component/QS-21 main peak is ?0.075, as measured by UV absorbance at 214 nm, methods for obtaining such extracts and related aspects.Type: GrantFiled: July 17, 2023Date of Patent: November 12, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Ahmad Taimour Baig, Juan Jose Diaz Garcia, Chad Austin Farrenburg, Kent Raymond Myers, Jeri Kay Sandvick, Jeb Yeatts Vandenburg
-
Patent number: 12138308Abstract: The present invention relates to a polymer complex for recognizing Helicobacter pylori and its uses, and in more detail, a water-soluble polymer-photosensitizer complex in which sialyllactose, which selectively binds to the surface of Helicobacter pylori, is conjugated, has excellent selectivity and binding power to the Helicobacter pylori strain, and the photosensitizer in the complex generates singlet oxygen when irradiated with laser to effectively induce the inactivation of Helicobacter pylori and it is intended to provide the complex as a polymer complex for recognizing Helicobacter pylori to effectively detect Helicobacter pylori in the gastrointestinal tract and to provide a Helicobacter pylori photodynamic therapy to solve the conventional antibiotic resistance problem.Type: GrantFiled: September 20, 2019Date of Patent: November 12, 2024Assignee: eNBiaR Inc.Inventors: Kun Na, Byeong Nam Im
-
Patent number: 12138309Abstract: The present invention describes topical formulations for use in photodynamic therapy (PDT) of skin affections, said formulations comprising a Zn-phthalocyanine derivative.Type: GrantFiled: March 6, 2020Date of Patent: November 12, 2024Assignee: MOLTENI THERAPEUTICS S.R.L.Inventors: Gabrio Roncucci, Lia Fantetti, Annalisa Cocchi, Moira Municchi, Francesco Giuliani, Silvia Tampucci, Daniela Monti, Giacomo Chiti
-
Patent number: 12138310Abstract: The invention relates primarily to a processing method of biopolymers by means of solvent/solvent mixtures or multiphase solvent systems by means of which said polymers can be changed in their mechanical and qualitative features and processed more easily.Type: GrantFiled: October 9, 2018Date of Patent: November 12, 2024Assignee: SolyPlus GmbHInventors: Richard Dolph Andersen, Annette Assogba-Zandt, Elena Maltseva, Andreas Voigt
-
Patent number: 12138311Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.Type: GrantFiled: February 28, 2020Date of Patent: November 12, 2024Assignee: Journey Medical CorporationInventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
-
Patent number: 12138312Abstract: Provided herein are oligonucleotides, cell penetrating peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.Type: GrantFiled: October 17, 2018Date of Patent: November 12, 2024Assignees: Sarepta Therapeutics, Inc., Massachusetts Institute of TechnologyInventors: Justin M. Wolfe, Colin M. Fadzen, Zi-Ning Choo, Rebecca L. Holden, Monica Yao, Gunnar J. Hanson, Bradley L. Pentelute
-
Patent number: 12138313Abstract: This disclosure relates to anti-cancer antibodies and methods of treatment, detection, and diagnosis using the same.Type: GrantFiled: March 21, 2024Date of Patent: November 12, 2024Assignee: Bluefin Biomedicine, Inc.Inventors: Hong Ren, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Tinglei Gu
-
Patent number: 12138314Abstract: This disclosure relates to anti-cancer antibodies and methods of treatment, detection, and diagnosis using the same.Type: GrantFiled: March 21, 2024Date of Patent: November 12, 2024Assignee: Bluefin Biomedicine, Inc.Inventors: Hong Ren, Scott Michael Lonning, Nels Eric Pederson, Klarisa Rikova, Aleksandr Tkachev, Tinglei Gu
-
Patent number: 12138315Abstract: It is an object to provide an antibody specifically binding to CD37-positive tumor cells such as malignant B-cell lymphoma, an antibody-drug conjugate comprising the antibody, a pharmaceutical composition having therapeutic effects on a tumor using the antibody, a method for treating a tumor using the aforementioned pharmaceutical composition, a method for producing the antibody, and a method for producing the antibody-drug conjugate, and the like. The present invention provides an anti-CD37 antibody-drug conjugate in which an antibody is conjugated to a drug linker represented by the following formula (wherein A represents a connecting position to the antibody) by a thioether bond, specifically, a humanized anti-CD37 antibody having internalization ability and an antibody-drug conjugate containing the antibody.Type: GrantFiled: January 12, 2024Date of Patent: November 12, 2024Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Tomoko Terauchi, Yuji Shinjo, Hajime Sugawara, Yusuke Shuchi, Riki Goto
-
Patent number: 12138316Abstract: The present invention provides an antibody-drug conjugate specifically binding to B7H3 and a pharmaceutical composition comprising the same. A method for using the antibody-drug conjugate of the present invention and use thereof are also provided herein.Type: GrantFiled: November 16, 2023Date of Patent: November 12, 2024Assignee: Duality Biologics (Suzhou) Co., Ltd.Inventors: Zhongyuan Zhu, Chen Zhong, Yu Zhang, Chenggang Li
-
Patent number: 12138317Abstract: A method for enhancing or restoring adhesion to cells that have partially or completely loss the ability to adhere to a substrate or other cells using nanosized clay crystallites.Type: GrantFiled: July 19, 2024Date of Patent: November 12, 2024Assignee: KING FAHD UNIVERSITY OF PETROLEUM AND MINERALSInventors: Sahel Nishat Abduljauwad, Habib-ur-Rehman Ahmed
-
Patent number: 12138318Abstract: There is described an AAV capsid protein having an amino acid sequence which has at least 98% identity to the sequence of SEQ ID NO: 3 or at least 94% identity to the sequence of SEQ ID NO: 4. Also described is a pharmaceutical composition, an AAV capsid and a viral particle comprising the capsid protein, a recombinant AAV vector comprising a nucleotide sequence which encodes for the capsid protein, and a host cell and a transgenic animal comprising the capsid protein or the vector. In addition, there is described a method of transferring a nucleic acid of interest into a mammal comprising introducing a recombinant AAV vector into the mammal, wherein the recombinant AAV vector comprises a gene of interest which is encapsidated into a capsid comprising the capsid protein.Type: GrantFiled: August 15, 2019Date of Patent: November 12, 2024Assignee: UCL BUSINESS LTDInventors: Amit Nathwani, Allison Dane
-
Patent number: 12138319Abstract: A human chimeric protein(1) is described, expressed by a viral vector (2) designed for treating patients affected by genetic disorders, composed of a first cDNA sequence [SEQ. 2] of a N-terminal extracellular portion of a human receptor (4) of low-density lipoproteins (5) (hLDLR), fused with a second cDNA sequence [SEQ. 3] of the human transferrin (7) (hTf).Type: GrantFiled: January 15, 2020Date of Patent: November 12, 2024Inventors: Lucio Pastore, Eleonora Leggiero
-
Patent number: 12138320Abstract: Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment.Type: GrantFiled: May 11, 2021Date of Patent: November 12, 2024Assignee: The University of ChicagoInventors: Raymond E. Moellering, Jae Won Chang
-
Patent number: 12138321Abstract: Provided herein are curcumin analogues that are able to interact with amyloid beta (A?) and to attenuate the copper-induced crosslinking of A?. Also provided herein are methods of using the compounds as imaging agents of amyloid beta and for the treatment of diseases associated with amyloid beta. Methods of preparing unlabeled and radiolabeled compounds useful for interacting with amyloid beta and pharmaceutical compositions are also provided.Type: GrantFiled: September 22, 2021Date of Patent: November 12, 2024Assignee: The General Hospital CorporationInventors: Chongzhao Ran, Anna Moore, Jian Yang
-
Patent number: 12138322Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.Type: GrantFiled: March 19, 2024Date of Patent: November 12, 2024Assignee: Vector Vitale IP LLCInventors: Peter Novak, Max Temnik, Oleksandr Balakin
-
Patent number: 12138323Abstract: The invention relates to an initiator system for curing a dental composition, the initiator system comprising a hydroperoxide component, a transition metal component, a polymerizable thiourea component, the polymerizable thiourea component comprising a thiourea moiety which is attached to a (meth)acrylate moiety through a C3-11 alkyl chain. The invention also relates to a dental composition comprising such an initiator system, and curable components, in particular curable components comprising acidic moieties.Type: GrantFiled: March 28, 2022Date of Patent: November 12, 2024Assignee: Solventum Intellectual Properties CompanyInventors: Kai U. Claussen, Johannes M. Leykauff, Wolf Steiger, Peter Bissinger
-
Patent number: 12138324Abstract: Base material arrangements having at least two layers can accommodate the addition of antifungal material (nanofiller), such as in denture base resin without significantly compromising the mechanical properties and/or translucency of the base material arrangements. Antifungal agents such as nanosilver and nanozirconia can be used to modify a surface layer of the material arrangements, such as the denture base, to overcome certain known shortcomings of the modified materials, e.g., typical acrylic resins containing nanosilver and nanozirconia.Type: GrantFiled: July 24, 2024Date of Patent: November 12, 2024Assignee: Imam Abdulrahman Bin Faisal UniversityInventors: Mohammed Moustafa Ahmed Gad, Reem Abualsaud, Ahmed Mohamed Rahoma, Shaimaa Mohamed Said Fouda, Ahmad M. Al-Thobity
-
Patent number: 12138325Abstract: A dental composition may have good handling properties and low polymerization shrinkage stress, and be capable of producing a cured product having desirable mechanical strength and excellent transparency. A dental composition may include a polymerizable monomer (A), a filler (B), and a polymerization initiator (C), wherein the polymerizable monomer (A) includes a polyfunctional (meth)acrylic monomer (a-1) having an aromatic ring but no hydroxyl group, and a polyfunctional (meth)acrylic monomer (a-2) having an alicyclic skeleton, and the polyfunctional (meth)acrylic monomer (a-1) and the polyfunctional (meth)acrylic monomer (a-2) have a mass ratio (a-1)/(a-2) of 30/70 to 95/5.Type: GrantFiled: November 26, 2019Date of Patent: November 12, 2024Assignee: KURARAY NORITAKE DENTAL INC.Inventors: Hayato Miyakawa, Hirotaka Horiguchi, Tatsuya Kajikawa
-
Patent number: 12138326Abstract: An oral care article for use in the oral cavity includes a water insoluble delivery carrier comprising solid hydrophilic particles comprising at least one bleaching agent. At least about 20 parts by weight of the solid hydrophilic particles dissolve in about 100 parts by weight of water, and/or the solid hydrophilic particles increase by volume and/or weight by at least about 50% in water. The particles are embedded in the carrier partially below the first surface and partially at or above the first surface of the solid hydrophobic delivery carrier. A concentration of the bleaching agent is from about 0.01% to about 15%, by weight of the article.Type: GrantFiled: October 26, 2023Date of Patent: November 12, 2024Assignee: The Procter and Gamble CompanyInventors: Paul Albert Sagel, Jayanth Rajaiah
-
Patent number: 12138327Abstract: A process for the preparation of a ready-to-use cosmetic, flowable cleaning agent, in which a powdered surfactant mixture is mixed with water in a specific weight ratio is described herein. A flowable cleaning agent obtainable by the process is also described.Type: GrantFiled: November 30, 2021Date of Patent: November 12, 2024Assignee: Henkel AG & Co. KGaAInventors: Marlene Battermann, Sylvia Kerl, Heike Schelges, Sameh Hasan Fares
-
Patent number: 12138328Abstract: A rheological solid composition comprising a crystallizing agent and an aqueous phase.Type: GrantFiled: April 8, 2021Date of Patent: November 12, 2024Assignee: The Procter & Gamble CompanyInventors: Matthew Lawrence Lynch, Brandon Philip Illie, Taotao Zhu, Jamie Lynn Dria
-
Patent number: 12138329Abstract: The present invention was made in view of the conventional art, and an object of the present invention is to provide a gel cleansing agent that has a pH of 7.5 or lower and is excellent in foaming property. The gel cleansing agent comprises: 2 to 11% by mass of polyoxyethylene alkyl ether carboxylate; 0.5 to 3% by mass of xyloglucan; and 0.2 to 3% by mass of a cationized xanthan gum, and the pH of 1% aqueous solution is 7.5 or lower.Type: GrantFiled: December 25, 2019Date of Patent: November 12, 2024Assignee: SHISEIDO HONEYCAKE INDUSTRIES CO., LTD.Inventors: Tetsuo Nishina, Kouki Harada, Yuta Shimizu, Uhei Tamura